CICC: Maintaining Kangfang Biotech (09926.HK) outperform industry rating with a target price of HK$184.0

According to the Securities Times Financial APP, CICC released a research report stating that the profit forecasts for Kangfang Biotech (09926.HK) in 2026 and 2027 remain unchanged. The bank maintains an outperform rating and a target price of 184.0 Hong Kong dollars (55.8% upside) based on the DCF model.